Literature DB >> 17120404

Diagnosis and management of pathological laughter and crying.

Josef Parvizi1, David B Arciniegas, Gary L Bernardini, Michael W Hoffmann, Jay P Mohr, Mark J Rapoport, Jeremy D Schmahmann, Jonathan M Silver, Stanley Tuhrim.   

Abstract

Patients with various neurologic disorders exhibit exaggerated or inappropriate episodes of laughter, crying, or both without an apparent motivating stimulus or in response to stimuli that would not have elicited such an emotional response before the onset of the underlying disease. During these episodes, patients have difficulty controlling their emotional expression according to the contextual information. In contrast, patients with mood disorders have a pervasive and sustained change in their emotional experience and thus exhibit spells of laughter or crying because of an underlying mania or depression. This article focuses on the clinical presentation, diagnosis, prevalence, and proposed pathophysiological mechanisms of and available treatment options for this clinical phenomenon.

Entities:  

Mesh:

Year:  2006        PMID: 17120404     DOI: 10.4065/81.11.1482

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  14 in total

Review 1.  Pathological laughing and crying : epidemiology, pathophysiology and treatment.

Authors:  Hal S Wortzel; Timothy J Oster; C Alan Anderson; David B Arciniegas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 2.  Current concepts in the pharmacotherapy of pseudobulbar affect.

Authors:  Erik P Pioro
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

Review 3.  Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.

Authors:  Lily P H Yang; Emma D Deeks
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

4.  Pharmacotherapy for the Pseudobulbar Affect in Individuals Who Have Sustained a Traumatic Brain Injury: a Systematic Review.

Authors:  Amelia J Hicks; Fiona J Clay; Jennie L Ponsford; Luke A Perry; Mahesh Jayaram; Rachel Batty; Malcolm Hopwood
Journal:  Neuropsychol Rev       Date:  2020-01-15       Impact factor: 7.444

5.  Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing.

Authors:  Martin Paspe Cruz
Journal:  P T       Date:  2013-06

6.  Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis.

Authors:  Kathryn C Fitzgerald; Amber Salter; Tuula Tyry; Robert J Fox; Gary Cutter; Ruth Ann Marrie
Journal:  Neurol Clin Pract       Date:  2018-12

7.  Brainstem Correlates of Pathological Laughter and Crying Frequency in ALS.

Authors:  Sicong Tu; Mengjie Huang; Jashelle Caga; Colin J Mahoney; Matthew C Kiernan
Journal:  Front Neurol       Date:  2021-07-08       Impact factor: 4.003

Review 8.  Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.

Authors:  Erik P Pioro
Journal:  Neurol Ther       Date:  2014-06-17

9.  An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.

Authors:  Gary L Pattee; James P Wymer; Catherine Lomen-Hoerth; Stanley H Appel; Andrea E Formella; Laura E Pope
Journal:  Curr Med Res Opin       Date:  2014-07-28       Impact factor: 2.580

Review 10.  Pseudobulbar affect: prevalence and management.

Authors:  Aiesha Ahmed; Zachary Simmons
Journal:  Ther Clin Risk Manag       Date:  2013-11-29       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.